TSAI, EING MEI,蔡英美,蔡英美,HSU, YA LING,许雅玲,許雅玲,KUO, PO LIN,郭柏麟,郭柏麟
申请号：
TW104102762
公开号：
TWI536985B
申请日:
2015.01.27
申请国别(地区):
TW
年份:
2016
代理人:
摘要：
Disclosed are a pharmaceutical composition for inhibiting phthalate-esters-induced breast cancer bone metastasis by targeting parathyroid hormone-related protein (PTHrP) using the plant or the seeds of Cassia tora L. or anthraquinone compounds, as well as the use therefor. Breast cancer generates PTHrP and interleukin-8 (IL-8) and decrease the expression of osteoprotegerin for inhibiting osteoclastogenesis after exposure to phthalate eatersare. The anthraquinone compounds include but not limited to physcion, emodin, chrysophanol and obtusifolin. Butyl-benzyl phthalate (BBP), di-2-ethylhexyl phthalate (DEHP) and dibutyl phthalate (DBP) are the models of phthalate esters applicably used in the present invention.揭露的是一種將決明、決明子或蒽醌類化合物製備用於藉由針對副甲狀腺素相關蛋白質而抑制由鄰苯二甲酸酯誘導的乳癌骨轉移的醫藥組合物及其用途,乳癌細胞暴露於鄰苯二甲酸酯的環境中而被誘導產生副甲狀腺素相關蛋白質及介白素-8,且乳癌細胞降低了用於抑制骨蝕細胞生成作用的保骨素的表現。蒽醌類化合物包括但不限於大黃素甲醚、大黃素、大黃酚及決明蒽醌,且鄰苯二甲酸二丁酯、鄰苯二甲酸甲苯基丁酯、鄰苯二甲酸二(2-乙基己基)酯等為在本發明中適用的鄰苯二甲酸酯的範例。
